Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema
15 déc. 2022 07h00 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential...
Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress
09 nov. 2022 16h05 HE
|
Rezolute, Inc.
Phase 2 proof-of-concept study of RZ402 expected to be initiated by the end of this year REDWOOD CITY, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage...
Rezolute to Present at the Jefferies London Healthcare Conference
01 nov. 2022 07h00 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential...
Rezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting
20 oct. 2022 07h00 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential...
Rezolute Reports Fourth Quarter and Full Year Fiscal 2022 Results and Highlights Company Progress
15 sept. 2022 16h05 HE
|
Rezolute, Inc.
Announced a $130 million registered direct offering and concurrent private placement priced at-the-market Late-breaking oral presentation from Phase 2b RIZE study of RZ358 presented at ESPE 2022 ...
Rezolute Announces Presentation at the 60th Annual ESPE Meeting
07 sept. 2022 07h00 HE
|
Rezolute, Inc.
Data from Phase 2b RIZE Study in congenital hyperinsulinism will be presented in oral presentation REDWOOD CITY, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a...
Rezolute Announces Promotion of Brian Roberts, M.D. to Chief Medical Officer
01 juin 2022 07h00 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential...
Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress
12 mai 2022 16h05 HE
|
Rezolute, Inc.
Announced a $130 million registered direct offering and concurrent private placement Positive topline results from Phase 2b RIZE study of RZ358 exceeded expectations and demonstrated highly...
Rezolute to Host Corporate Update Call on May 4, 2022
04 mai 2022 16h01 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential...
Rezolute, Inc. Announces Closing of Registered Direct Offering
04 mai 2022 09h33 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential...